Every inquiry is reviewed by ARI's medical and operations leadership, not passed through a generic queue.
Physician-Led Clinical Research Site Network
Clinical research works better when the right sites are ready from the start.
ARI is a physician-led research network in Los Angeles, San Francisco, and Las Vegas, bringing geographic reach and deep specialty-specific expertise to programs that need more than a site list.
Includes recommended sites, patient access, investigator availability, and the startup issues that matter early.
Principal investigator-led programs with top-enrolling status across multiple specialty studies.
Retina, glaucoma, dry eye, and thyroid eye disease experience, with operations built for specialty and device studies.
Clinical focus
Specialty depth for studies that need more than a database count.
ARI is strongest when a protocol needs the right investigators, careful imaging, reachable patients, and follow-up that holds together visit after visit.
AMD, geographic atrophy, diabetic eye disease, RVO, inherited retinal disease
Experienced investigators and imaging workflows for chronic retina programs, close follow-up, and longitudinal endpoints.
Glaucoma, cornea, dry eye, ocular surface, and device programs
Site teams familiar with visit-heavy protocols, visual function testing, imaging endpoints, and sponsor documentation standards.
Thyroid eye disease, rare disease, pediatric, and complex interventional studies
Centralized feasibility review helps sponsors understand which sites, markets, and investigators fit first.
Sponsor pathway
A simpler path from first look to serious review.
ARI gives clinical operations, medical, and procurement teams enough information to judge fit quickly and keep the conversation moving.
Review the network
Confirm geography, specialty depth, and patient access across Los Angeles, San Francisco, and Las Vegas.
Open network reviewDownload the sponsor deck
Use the capabilities deck while your team reviews fit, timing, and required site resources.
Get the deckShare the study basics
Send what you have, even early. ARI can review study type, markets, timing, and required procedures.
Start intakeGet a focused response
ARI returns recommended sites, practical considerations, and next-step follow-up from leadership.
Contact sponsor deskSponsor briefing room
What sponsor teams usually need for the first internal pass.
ARI answers the questions that come up first: who owns the relationship, which markets fit, what startup may require, and who follows up after the first review.
One sponsor-facing team coordinates every site instead of asking your team to run parallel site conversations.
Ophthalmology-rooted investigators support rare disease, pediatric, imaging, and device-heavy programs.
Standardized SOPs, training, and documentation keep activation consistent from site to site.
Janelle Gonzalez and Daniel Lemor stay on the sponsor path for handoff and escalation.
Internal handoff assets
What your team can use right now.
- Capabilities deck for medical, clinical operations, and procurement review.
- Network page organized around Los Angeles, San Francisco, and Las Vegas.
- Sponsor inquiries reviewed directly by ARI's medical and operations leadership.
- Direct sponsor desk contacts for introductions, timing questions, or internal follow-up.
Network footprint
Research sites in Los Angeles, San Francisco, and Las Vegas.
Three western markets give sponsors a practical recruitment footprint, coordinated through one network relationship and one sponsor team.
California
Los Angeles & San Francisco
Major metropolitan research markets with diverse patient populations and strong referral networks.
Nevada
Las Vegas
A large retirement-age population with high disease prevalence — particularly valuable for age-related conditions and chronic disease programs.
One conversation, multiple sites
One feasibility conversation covers every ARI site, without duplicating sponsor meetings or startup work.
30,000+ direct. 350,000+ affiliated.
30,000+ patients in ARI's internal database, with access to 350,000+ through affiliated networks and referrals.
Phase I–IV. Interventional. Device.
Full-phase capability including complex interventional, rare disease, pediatric, and device studies.